MAT, or medication-assisted treatment, is the use of FDA-approved medications combined with counseling and behavioral therapy to treat substance use disorders, particularly opioid and alcohol addiction. It’s considered a “whole-patient” approach, meaning it addresses both the physical and psychological sides of addiction rather than relying on willpower or therapy alone. MAT is one of the most effective treatments available for opioid use disorder, reducing overdose deaths by as much as 59% compared to no medication treatment.
How MAT Works in the Brain
Opioid addiction changes how the brain’s receptors function. When someone uses opioids repeatedly, their brain adapts to expect those chemicals, creating physical dependence. MAT medications work by interacting with the same receptors that opioids target, but in controlled, predictable ways that reduce cravings and prevent withdrawal without producing the dangerous highs of street drugs.
There are three categories of medications used, and they each interact with opioid receptors differently. Full agonists activate the receptor completely, mimicking the effects of opioids but in a stable, supervised way. Partial agonists activate the receptor only partway, creating a ceiling effect where the response plateaus no matter how much you take. Antagonists block the receptor entirely, so if you use opioids while on the medication, you feel no effect. These three approaches give doctors flexibility to match the treatment to each person’s situation.
Medications for Opioid Use Disorder
Three FDA-approved medications form the backbone of MAT for opioid addiction:
Methadone is a full agonist, meaning it activates opioid receptors in a way that prevents withdrawal symptoms and reduces cravings. Because it does mimic opioid effects, it carries some potential for misuse and is dispensed through specialized clinics rather than regular pharmacies. Patients typically visit the clinic daily, especially early in treatment. The starting dose is deliberately low (usually 10 to 20 mg) and increased gradually over weeks until cravings and withdrawal symptoms are controlled, often landing somewhere in a range that the prescribing clinician determines based on the individual’s response.
Buprenorphine is a partial agonist. In practical terms, this means it eases withdrawal and reduces cravings, but its effects level off at a certain point. If someone takes opioids while on buprenorphine, the medication actually blocks much of the opioid’s effect because it’s already occupying the receptors. Treatment typically starts at 4 mg on the first day, then increases over subsequent days until reaching an effective maintenance range, generally between 8 and 24 mg daily. Buprenorphine can be prescribed from a regular doctor’s office, making it more accessible than methadone. A 2025 DEA rule now allows patients to receive up to a six-month supply of buprenorphine after a telephone consultation, with an in-person visit required for further prescriptions.
Naltrexone is an antagonist. It blocks opioid receptors completely, so it produces no opioid-like effects at all and has no potential for misuse. The tradeoff is that a person must be fully detoxed before starting it, because taking naltrexone while opioids are still in the system triggers immediate, severe withdrawal. It’s available as a daily pill or a monthly injection.
MAT for Alcohol Use Disorder
MAT isn’t only for opioid addiction. Two first-line medications are used for alcohol use disorder: naltrexone (the same drug used for opioids, taken at a 50 mg daily oral dose for alcohol) and acamprosate. Naltrexone reduces the rewarding sensation of drinking, making alcohol less appealing. Acamprosate helps stabilize brain chemistry that’s been disrupted by long-term alcohol use, reducing the persistent discomfort that drives people to drink again.
Both medications show meaningful results. In clinical trials, acamprosate prevented one additional person from returning to any drinking for every 11 people treated, while oral naltrexone achieved the same for every 18 people treated. A third medication, disulfiram, works differently: it causes unpleasant physical reactions (nausea, flushing, headaches) if you drink while taking it, creating a strong deterrent.
The Counseling Component
Medication alone is only half of MAT. The other half is behavioral therapy, which addresses the habits, triggers, and emotional patterns that drive substance use. Most MAT programs include individual, group, or family counseling. About two-thirds of behavioral health services in MAT settings are delivered through these therapy or counseling formats, with another 30% provided as part of structured behavioral health programs.
The specific type of therapy varies by program and patient need. Cognitive-behavioral therapy helps people identify and change thought patterns that lead to use. Relapse prevention counseling builds practical strategies for handling high-risk situations. Some programs use contingency management, which provides small rewards for meeting treatment goals like negative drug tests. The combination of medication to manage the physical dimension and therapy to address the psychological one is what makes MAT more effective than either approach alone.
How Effective MAT Is
The strongest evidence for MAT comes from opioid use disorder treatment. A study analyzing data from over 17,500 adults in Massachusetts who survived an opioid overdose found that those who received methadone had a 59% lower risk of dying from a subsequent overdose over the following 12 months. Those on buprenorphine had a 38% lower risk. These are among the largest reductions in mortality seen in addiction treatment research.
MAT also improves daily functioning in ways that go beyond survival. People in treatment are more likely to hold jobs, maintain relationships, and avoid criminal activity. One area where buprenorphine shows a clear advantage over methadone is fatigue: research comparing the two found that 52 fewer patients per 1,000 reported fatigue on buprenorphine than on methadone. Neither medication appears to worsen insomnia compared to placebo.
What Starting MAT Looks Like
Treatment begins with screening and assessment to determine the type and severity of the substance use disorder and which medication is the best fit. For opioid use disorder, the choice often comes down to the person’s history, their access to treatment facilities, and their goals.
The first phase is called induction: starting the medication at a low dose and carefully increasing it. For methadone, this means starting at 10 to 20 mg daily and being observed for a few hours afterward to make sure the dose is tolerated. The dose is then increased by small amounts, no more than 20 mg per week, until symptoms stabilize. For buprenorphine, the process moves faster. A person must already be in mild to moderate withdrawal before taking the first dose (otherwise the partial agonist can trigger worse withdrawal), and the dose can be adjusted more quickly over the first few days.
Once the right dose is reached, the stabilization phase begins. Cravings and withdrawal symptoms should be minimal at this point, and the focus shifts to building a routine around counseling, avoiding triggers, and gradually returning to normal life. Some people stay on MAT for months, others for years. There’s no fixed timeline, and research consistently shows that longer treatment is associated with better outcomes. Stopping medication too early is one of the most common reasons for relapse.
Side Effects to Expect
Like any medication, MAT drugs come with side effects, though most people find them manageable compared to the alternative of active addiction. Methadone is more likely to cause fatigue and drowsiness. Buprenorphine tends to be better tolerated on that front, with significantly lower rates of fatigue in head-to-head comparisons. Both can cause constipation, sweating, and changes in sleep patterns, though clinical data shows insomnia rates are similar to placebo for both medications.
Naltrexone’s main challenge isn’t side effects during treatment but the requirement to be fully detoxed first, which can be a significant hurdle. Once started, common side effects include nausea, headache, and fatigue, which typically improve over the first few weeks. The injectable form avoids the need to remember a daily pill but can cause soreness at the injection site.
Access and Availability
One of the biggest shifts in MAT access came when the federal government eliminated the special waiver (known as the X-waiver) that previously limited which doctors could prescribe buprenorphine. Any provider with a standard controlled substances license can now prescribe it. This has expanded access significantly, especially in rural areas where specialized addiction clinics are scarce.
Telehealth has further lowered barriers. Under current DEA rules, a patient can receive an initial buprenorphine prescription through a phone call, with up to a six-month supply authorized before an in-person visit is required. Methadone still requires visits to a certified opioid treatment program, though some states have expanded take-home dose policies. Naltrexone, because it has no misuse potential, can be prescribed by any healthcare provider without special certification.